22873-28-5

Basic information

• Product Name: 4-ETHYLPHENYLMAGNESIUM BROMIDE
• Synonyms: 4-ETHYLPHENYLMAGNESIUM BROMIDE;4-ETHYLPHENYLMAGNESIUM BROMIDE, 0.5M SOLUT TION IN TETRAHYDROFURAN;4-ethylphenylmagnesium bromide solution;4-Ethylphenylmagnesium bromide solution 0.5 in THF;4-Ethylphenylmagnesium bromide, 0.5M solution in THF, AcroSeal;4-EthylphenylMagnesiuM broMide, 0.5M in 2-MeTHF;4-Ethylphenylmagnesium bromide 1M solution in THF;4-EthylphenylMagnesiuM broMide, 0.5M solution in THF, J&KSeal
• CAS NO: 22873-28-5
• Molecular Formula: C₈H₉BrMg
• Molecular Weight: 209.37
• Product Categories: Aryl;Grignard Reagents;Organometallic Reagents
• Mol File: 22873-28-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 65 °C
• Flash Point: 1 °F
• Appearance: Clear yellow to brown/Solution
• Density: 0.950 g/mL at 25 °C
• Vapor Pressure: 9.21mmHg at 25°C
• Storage Temp.: 2-8°C
• Water Solubility: Reacts with water.
• Sensitive: Air & Moisture Sensitive
• CAS DataBase Reference: 4-ETHYLPHENYLMAGNESIUM BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHYLPHENYLMAGNESIUM BROMIDE(22873-28-5)
• EPA Substance Registry System: 4-ETHYLPHENYLMAGNESIUM BROMIDE(22873-28-5)

Safety Data

• Hazard Codes: F,C,Xn
• Statements: 11-14/15-19-34-40-36/37-14
• Safety Statements: 16-26-33-36/37/39-43-45-36/37-8
• RIDADR: UN 2924 3/PG 2
• WGK Germany: 1
• HazardClass: 3
• Hazardous Substances Data: 22873-28-5(Hazardous Substances Data)

Usage

Chemical Properties

Light brown liquid

Uses

4-Ethylphenylmagnesium bromide, 0.5M in 2-MeTHF is used as a pharmaceutical intermediate.

InChI:InChI=1/C8H9.BrH.Mg/c1-2-8-6-4-3-5-7-8;;/h4-7H,2H2,1H3;1H;/q-1;;+2/p-1

Upstream product

• 80086-16-4 4-(1-methyl-1,2,3,4-tetrazol-5-yl)thiobutyronitrile 
• 1585-07-5 1-bromo-4-ethylbenzene 
• 99-90-1 para-bromoacetophenone 
• 108-86-1 bromobenzene 

Downstream Products

• 308256-12-4 chloro-(4-ethyl-phenyl)-diisopropyl-silane 
• 1204220-04-1 (5-bromo-2-chloro-4-fluorophenyl)(4-ethylphenyl)methanone 
• 1345021-03-5 6-aminosulfonyl-3-(4-ethylphenyl)-1,2-benzoisothiazole 1,1-dioxide 
• 124157-28-4 tris(4-α-chloroethyl phenyl)boroxine 
• 16396-62-6 2,4,6-tris-(4-vinylphenyl)cyclotriboroxane 
• 782504-43-2 (4-ethylphenyl)(pyridin-4-yl)methanol 
• 5731-13-5 4-(4-ethylphenyl)benzoic acid 
• 185416-23-3 [2-(4-Ethyl-phenyl)-6-methoxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 60423-28-1 2-[(4-Ethyl-phenyl)-phenyl-methyl]-indan-1,3-dione 
• 155337-52-3 RTI 83 
• 619-64-7 p-ethylbenzoic acid 
• 89610-92-4 7-(4-ethylphenyl)tropylidene 
• 17878-04-5 Dichlor-methyl-<4-ethyl-phenyl>-silan 
• 79568-32-4 2-(4-ethylphenyl)-4,4-dimethyl-2-oxazoline 

Relevant articles and documents

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

TETRAZOLE DERIVATIVES, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME

Tetrazole derivatives of the formula: STR1 wherein R 1 is a lower alkykl, phenyl or a group of the formula:--S(O) l--A--(X) m--R 3, and R 2 is hydrogen, a lower alkyl, phenyl or a cycloalkyl when R 1 is the group--S(O) l--A--(X) m--R 3, or R 2 is a group of the formula:--B--CO--R 4 when R 1 is a lower alkyl or phenyl and a pharmaceutically acceptable salt thereof, which have prophylactic or therapeutic activities against peptic and/or duodenal ulcers and are useful as an anti-ulcer drug; processes for the preparation of the tetrazole derivatives; and pharmaceutical composition containing said tetrazole derivatives.